Fusion Pharmaceuticals Corporate Presentation 2023

Fusion Pharmaceuticals, a clinical-stage biotech company, presents its pipeline progress including Phase 1 trials for FPI-2059, acquisition of a Phase 2 PSMA-targeted prostate cancer program, and collaboration advances with AstraZeneca. The company highlights strategic supply agreements for actinium-225, a key therapeutic component in its targeted radiopharmaceutical platform.